Plastic and Reconstructive Surgery Publishes UltraShape's Basic Science and Pre-Clinical Research Demonstrating Proven Tissue Effects



    
    - Peer-Reviewed Data Support Unique Focused Ultrasound Technology for
    Non-Invasive Fat Reduction and Body Contouring
    

    YOQNEAM, Israel, Jan. 26 /CNW/ - UltraShape, a global leader in
non-invasive fat reduction and body contouring, today announced the
publication of extensive scientific and pre-clinical research data on its
patented focused ultrasound technology in Plastic and Reconstructive
Surgery(R). The publication by S. Brown, PhD et al entitled "Characterization
of Non-thermal Focused Ultrasound for Non-invasive Selective Fat Cell
Disruption (lysis): Technical and Pre-clinical Assessment" is currently
available on PRS Advance Online at http://www.plasreconsurg.com, the Website
for Plastic and Reconstructive Surgery(R), the Journal of the American Society
of Plastic Surgeons.
    "This extensive research confirms that the UltraShape(R) Contour I(TM)
system is the first non-invasive technology to produce a non-thermal focused
acoustic field at a controlled subcutaneous target resulting in stable
cavitation," said Spencer Brown, PhD, Director of Research, Plastic Surgery
Department at the University of Texas Southwestern Medical Center, and member
of the UltraShape Medical Advisory Board. "Histopathologist reviewed specimens
of dermal and sub-dermal tissue, including subcutaneous fat, demonstrated
selective fat cell destruction with preservation of surrounding critical
structures such as skin, blood vessels, nerves and connective tissue. No
epidermal or dermal changes were observed clinically or histologically."
    "UltraShape has always taken the high road and based their claims on
science and sound research. This published research demonstrates a
well-understood mechanism of action with proven tissue effects," said Jeffery
M. Kenkel, M.D., F.A.C.S., Vice Chairman and Professor of Plastic Surgery at
the University of Texas Southwestern Medical Center, and Chairman, UltraShape
Medical Advisory Board. "UltraShape is the first non-invasive aesthetic
technology to be scientifically validated by such comprehensive pre-clinical
research."
    "The publication of our extensive scientific and pre-clinical research in
plastic surgery's premier peer-reviewed journal is yet another significant
milestone for our company. This research further validates our non-thermal
focused ultrasound technology and its unique ability to target and selectively
destroy fat cells for non-invasive fat reduction and body contouring," said
Assaf Eyal, President and Chief Executive Office of UltraShape Ltd. "The
combination of this new peer-reviewed published scientific research, our
previously published clinical results and over three and a half years clinical
experience outside the U.S., clearly places the UltraShape technology in a
class by itself."

    About the UltraShape(R) Contour I(TM)

    The UltraShape Contour I system, which is authorized for marketing
outside the U.S., incorporates patented non-thermal selective focused
ultrasound technology. Contour I, is the first scientifically and clinically
proven non-invasive fat reduction and body contouring device for both men and
women. The device is designed to produce mechanical, non-thermal, acoustic
effects which target and selectively disrupt fat cells, leaving surrounding
critical structures such as skin, blood vessels, nerves, and connective tissue
intact.
    The UltraShape procedure is available in 57 countries and over 100,000
patient treatments have been performed worldwide with high patient
satisfaction. The UltraShape procedure is guided by proprietary real-time
tracking and guidance technology designed to deliver smooth, uniform body
contouring results. The software provides a pre-determined treatment algorithm
designed to minimize risk of contour irregularities, a common side effect of
liposuction. The UltraShape procedure is performed during a convenient,
"walk-in, walk-out" session carried out in an office-based environment; it
requires no anesthesia or sedation. After treatment, patients immediately
resume their daily routines with no need for maintenance treatments.
    The UltraShape Contour I received the CE Mark in 2005 and a medical
device license from Health Canada in 2007. The Contour I system is not
available for sale in the U.S. and the Contour Plus system is an
investigational product limited by U.S. law to investigational use only.

    About UltraShape

    UltraShape is redefining aesthetic medicine by developing, manufacturing
and marketing innovative non-invasive technologies for body contouring. The
UltraShape proprietary non-invasive body contouring technology is based on
focused ultrasound that targets and selectively disrupts fat cells without
affecting surrounding structures. Founded in 2000, UltraShape is a privately
held and venture backed company. The UltraShape system is not approved by the
FDA for marketing in the United States. For more information visit
http://www.ultrashape.com.





For further information:

For further information: Inbar Elfasy, UltraShape Ltd., +972-4-9094045,
inbar@ultrashape.com; Maria Jenkerson, UltraShape North America, (925)
242-2585, mjenkerson@ultrashape.com

Organization Profile

ULTRASHAPE LTD.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890